# A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD

> **NCT06843408** · PHASE1,PHASE2 · RECRUITING · sponsor: **Incyte Corporation** · enrollment: 30 (estimated)

## Conditions studied

- Chronic Graft-versus-host-disease

## Interventions

- **DRUG:** INCA034176

## Key facts

- **NCT ID:** NCT06843408
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-25
- **Primary completion:** 2026-07-03
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06843408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06843408, "A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06843408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*